Clinic
Center for Orthopedic Research and Education, LLC
Center for Orthopedic Research and Education, LLC was paid $36.41M by Medicaid between Jan 2018 and Dec 2024, across 118 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 21% of everything it billed.
33Billing provider infoCENTER FOR ORTHOPEDIC RESEARCH AND EDUCATION, LLC
PHOENIX, AZ 85023
PHOENIX, AZ 85023
33aNPI1427095801assigned 06/02/2006
33bProvider typeMagnetic Resonance Imaging (MRI) Clinic/Center
28Total paid$36.41M
24GClaims814,825
24DCodes billed118
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Magnetic Resonance Imaging (MRI) Clinic/Center providers in Arizona
Rank by total paid#1 of 7
Median peer was paid$99K
This provider vs. median367×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 85,227 | $3.29M | |
| 2019 | 89,467 | $3.49M | |
| 2020 | 106,766 | $4.81M | |
| 2021 | 115,346 | $5.74M | |
| 2022 | 135,768 | $6.26M | |
| 2023 | 148,787 | $6.68M | |
| 2024incomplete | 133,464 | $6.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 138,896 | 130,913 | $7.46M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 19% | 142,712 | 50,599 | $6.92M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 116,728 | 110,628 | $4.73M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 8.9% | 54,564 | 52,313 | $3.24M |
| 20610 | 4.2% | 35,235 | 29,542 | $1.53M | |
| 64483 | 3.8% | 7,274 | 6,707 | $1.39M | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 3.6% | 39,338 | 15,565 | $1.32M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 3.0% | 62,037 | 24,401 | $1.08M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.7% | 11,226 | 10,971 | $992K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.7% | 16,299 | 6,727 | $636K |
| 97161 | 1.7% | 8,807 | 8,609 | $603K | |
| 95886 | 1.4% | 4,354 | 4,149 | $494K |
106 more codes
| J0897 | Injection, denosumab, 1 mg | 1.3% | 1,256 | $470K |
| 72100 | 1.1% | 15,806 | $406K | |
| 73564 | 1.1% | 13,531 | $402K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 8,320 | $362K |
| 73630 | <1% | 13,511 | $306K | |
| 27447 | <1% | 413 | $301K | |
| 73030 | <1% | 12,680 | $272K | |
| 64635 | <1% | 934 | $236K | |
| 73130 | <1% | 8,594 | $228K | |
| 99223 | Prolong inpt eval add15 m | <1% | 1,822 | $221K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 40,882 | $219K |
| 36475 | <1% | 291 | $204K | |
| 73610 | <1% | 7,702 | $195K | |
| 64493 | <1% | 1,147 | $171K | |
| 73110 | <1% | 5,587 | $167K | |
| 64636 | <1% | 905 | $137K | |
| J7318 | Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | <1% | 140 | $128K |
| 95913 | <1% | 442 | $111K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,984 | $83K |
| 93970 | <1% | 714 | $82K | |
| 72040 | <1% | 2,891 | $78K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 272 | $76K |
| 64494 | <1% | 930 | $68K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 981 | $68K |
| 20611 | <1% | 629 | $44K | |
| 72110 | <1% | 1,116 | $43K | |
| 95911 | <1% | 234 | $43K | |
| 73502 | <1% | 1,503 | $42K | |
| 98980 | <1% | 1,102 | $40K | |
| 62321 | <1% | 229 | $39K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 540 | $39K |
| 95910 | <1% | 253 | $39K | |
| 73560 | <1% | 1,464 | $37K | |
| 95912 | <1% | 168 | $35K | |
| 64484 | <1% | 526 | $35K | |
| 77002 | <1% | 446 | $33K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,444 | $33K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 437 | $31K |
| 36465 | <1% | 27 | $29K | |
| 64721 | <1% | 93 | $27K | |
| 20552 | <1% | 1,102 | $27K | |
| 73562 | <1% | 970 | $24K | |
| 99426 | <1% | 509 | $23K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 911 | $22K |
| 64495 | <1% | 336 | $21K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 273 | $18K |
| 97162 | <1% | 265 | $18K | |
| 27096 | <1% | 120 | $17K | |
| 93925 | <1% | 89 | $15K | |
| 95885 | <1% | 215 | $14K | |
| J3111 | Injection, romosozumab-aqqg, 1 mg | <1% | 12 | $14K |
| 97164 | <1% | 244 | $12K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,647 | $11K |
| 64615 | <1% | 159 | $11K | |
| 77073 | <1% | 284 | $11K | |
| J7324 | Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | <1% | 74 | $10K |
| 22853 | <1% | 40 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,635 | $10K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 427 | $9K |
| 29848 | <1% | 15 | $9K | |
| 20526 | <1% | 117 | $9K | |
| 20550 | <1% | 254 | $9K | |
| 11721 | <1% | 430 | $8K | |
| 62323 | <1% | 41 | $6K | |
| 0012A | <1% | 180 | $6K | |
| 0011A | <1% | 183 | $6K | |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 83 | $5K |
| 98981 | <1% | 110 | $5K | |
| 73070 | <1% | 223 | $5K | |
| 98977 | <1% | 113 | $5K | |
| 99205 | Prolong outpt/office vis | <1% | 45 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,690 | $4K |
| 73140 | <1% | 111 | $4K | |
| Q4010 | Cast supplies, short arm cast, adult (11 years +), fiberglass | <1% | 208 | $4K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 349 | $4K |
| 29075 | <1% | 44 | $3K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 376 | $3K |
| 99424 | <1% | 45 | $2K | |
| 98975 | <1% | 108 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 55 | $2K |
| 99221 | <1% | 33 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 5,317 | $2K |
| Q4038 | Cast supplies, short leg cast, adult (11 years +), fiberglass | <1% | 51 | $1K |
| 95816 | <1% | 41 | $1K | |
| 99427 | <1% | 25 | $1K | |
| 95909 | <1% | 12 | $1K | |
| 76942 | <1% | 42 | $1K | |
| 20553 | <1% | 40 | $1K | |
| 93971 | <1% | 14 | $1K | |
| 73600 | <1% | 62 | $1K | |
| 72050 | <1% | 25 | $1K | |
| 73565 | <1% | 28 | $907.96 | |
| 73100 | <1% | 33 | $819.23 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 197 | $736.60 |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 13 | $675.98 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 147 | $359.71 |
| 20600 | <1% | 13 | $267.45 | |
| 20605 | <1% | 13 | $228.63 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 32 | $200.33 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 127 | $189.99 |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 28 | $116.04 |
| 99499 | <1% | 87 | $0.22 | |
| 91301 | 0% | 129 | $0.00 | |
| 99024 | 0% | 42 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 282 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 484 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJACOFSKY, DAVID (MD -CEO)
| Provider | Location | Paid |
|---|---|---|
| Hopco Flagstaff Asc Holdings, LLC | Flagstaff, AZ | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.